Co-delivery of dual-drugs with nanoparticle to overcome multidrug resistance
Co-delivery of dual-drugs with nanoparticle to overcome multidrug resistance
复制标题
DOI：
10.18088/ejbmr.2.2.2016.pp12-18
复制
发表时间：
2016-04
期刊：
影响因子：
11.2
通讯作者：
Yuan Sun;Chen Kang;Aili Zhang;Fei Liu;Jinglu Hu;Xiao Zhong;Jing Xie
中科院分区：
文献类型：
--
作者：
Yuan Sun;Chen Kang;Aili Zhang;Fei Liu;Jinglu Hu;Xiao Zhong;Jing Xie
多药耐药（MDR）已成为恶性肿瘤化疗的重要障碍。由于MDR的出现，需要更高剂量的化疗药物，最终导致患者无法耐受的毒性和死亡。多药耐药与一般的耐药不同，多药耐药使多种化疗药物的疗效降低，导致细胞内药物浓度降低，不能杀死足够的癌细胞。由于联合用药的药代动力学特性不同，多种化疗药物的联合给药不能克服MDR，只能为患者带来有限的临床优势。纳米医学和纳米技术的最新进展使生物医学科学家能够以预定义的释放模式将具有相似或不同作用机制的多种药物递送到癌细胞中。因此，将纳米技术与共递送技术相结合，具有选择性递送多种药物以克服MDR并使癌症患者受益的巨大潜力。
Multidrug resistance (MDR) is becoming a significant obstacle for chemotherapeutic treatment in the battle against malignant cancers. Because of the emergence of MDR, higher doses of chemotherapeutic drugs are needed which eventually leads to intolerable toxicity and the death of patients. Different from the normal drug resistance that only resists to the previously administrated drugs, multidrug resistance diminishes the efficacies of a wide range of chemotherapeutic drugs, causing the decrease of intracellular drug concentration and the failure of killing enough cancer cells. Co-administration of multiple chemotherapeutic drugs cannot overcome MDR due to the different pharmacokinetic properties of combined drugs and only brings limited clinical advantage for the patients. Recent progress in nanomedicine and nanotechnology has enabled biomedical scientists to deliver multiple drugs of similar or different acting mechanisms into cancer cells with a predefined releasing profile. Thus, combining nanotechnology and co-delivery technique has the great potential to selectively deliver multiple drugs to overcome MDR and benefit cancer patients.